DUSA will halt a midstage trial of skin cancer therapy Levulan

08/8/2010 | Reuters

DUSA Pharmaceuticals plans to end a midstage study of its Levulan photodynamic therapy, after the FDA declined to give orphan-drug designation to the treatment. The drug is used to prevent skin cancer in organ transplant patients.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care